Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease

Kyoungjune Pak, Hae Kyung Shin, Eun Joo Kim, Jae Hyeok Lee, Chulhyoung Lyoo, Jongsang Son, Myung Jun Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. Methods: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on 123 I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ( 123 I-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5% of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. Results: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal 123 I-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 × 10 −3 , p = 0.009; putamen, estimate = 7.04 × 10 −3 , p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 × 10 −3 , p = 0.008; putamen, estimate = 2.34 × 10 −3 , p = 0.025). Conclusion: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD.

Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalParkinsonism and Related Disorders
Volume51
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

Corpus Striatum
Parkinson Disease
Weight Loss
Body Mass Index
Caudate Nucleus
Putamen
Linear Models
Nortropanes
Emission-Computed Tomography
Body Weight Changes
Positron-Emission Tomography
Disease Progression
Homeostasis
Biomarkers
Body Weight

All Science Journal Classification (ASJC) codes

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Pak, Kyoungjune ; Shin, Hae Kyung ; Kim, Eun Joo ; Lee, Jae Hyeok ; Lyoo, Chulhyoung ; Son, Jongsang ; Lee, Myung Jun. / Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease. In: Parkinsonism and Related Disorders. 2018 ; Vol. 51. pp. 67-72.
@article{74521bfcc1164fc380fdd0f6b5a9d58d,
title = "Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease",
abstract = "Introduction: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. Methods: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on 123 I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ( 123 I-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5{\%} of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. Results: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal 123 I-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 × 10 −3 , p = 0.009; putamen, estimate = 7.04 × 10 −3 , p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 × 10 −3 , p = 0.008; putamen, estimate = 2.34 × 10 −3 , p = 0.025). Conclusion: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD.",
author = "Kyoungjune Pak and Shin, {Hae Kyung} and Kim, {Eun Joo} and Lee, {Jae Hyeok} and Chulhyoung Lyoo and Jongsang Son and Lee, {Myung Jun}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.parkreldis.2018.02.044",
language = "English",
volume = "51",
pages = "67--72",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",

}

Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease. / Pak, Kyoungjune; Shin, Hae Kyung; Kim, Eun Joo; Lee, Jae Hyeok; Lyoo, Chulhyoung; Son, Jongsang; Lee, Myung Jun.

In: Parkinsonism and Related Disorders, Vol. 51, 01.06.2018, p. 67-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease

AU - Pak, Kyoungjune

AU - Shin, Hae Kyung

AU - Kim, Eun Joo

AU - Lee, Jae Hyeok

AU - Lyoo, Chulhyoung

AU - Son, Jongsang

AU - Lee, Myung Jun

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Introduction: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. Methods: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on 123 I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ( 123 I-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5% of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. Results: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal 123 I-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 × 10 −3 , p = 0.009; putamen, estimate = 7.04 × 10 −3 , p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 × 10 −3 , p = 0.008; putamen, estimate = 2.34 × 10 −3 , p = 0.025). Conclusion: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD.

AB - Introduction: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. Methods: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on 123 I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane ( 123 I-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5% of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. Results: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal 123 I-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 × 10 −3 , p = 0.009; putamen, estimate = 7.04 × 10 −3 , p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 × 10 −3 , p = 0.008; putamen, estimate = 2.34 × 10 −3 , p = 0.025). Conclusion: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD.

UR - http://www.scopus.com/inward/record.url?scp=85042701333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042701333&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2018.02.044

DO - 10.1016/j.parkreldis.2018.02.044

M3 - Article

VL - 51

SP - 67

EP - 72

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -